Gene Biotechnology Enterprises (Gene Bio Medical) has formed a strategic partnership with the Canadian Hub for Health Intelligence and Innovation in Infectious Diseases (HI³) for creating diagnostic solutions.
The partnership is part of an initiative named ‘Pandemic preparedness engaging primary care and emergency departments (PREPARED)’.
Upstream Lab founder and director and the University of Toronto associate professor Dr Andrew Pinto is leading the project.
The project has four-pronged objectives: integrating point-of-care tests, linking patients to trials, improving surveillance and accelerating the creation of diagnostics.
As part of the collaboration, Gene Bio Medical will work with HI³ to focus on commercialising and manufacturing aspects of the project, which intends to involve primary care and emergency departments across six Canadian provinces.
For supporting the project’s fourth objective, the company will speed up the creation and implementation of innovative diagnostic solutions.
Gene Bio Medical CEO Jessica Hu said: “We're proud to collaborate with HI³ and contribute to the PREPARED project. Our continued involvement in initiatives under the CBRF/BRIF program demonstrates our commitment to advancing global health solutions.”
HI3 is one of the five hubs assessing research and development projects for the Biosciences Research Infrastructure Fund (BRIF) and the Canada Biomedical Research Fund (CBRF).
It is a coalition of hospital, academic and research networks, government, industry, not-for-profit and community partners including the University of Toronto.
Gene Bio Medical, which serves as the primary commercial and biomanufacturing partner, works with universities and worldwide partners to revolutionise healthcare.
